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Recent studies have shown that both glomerular and
tubulointerstitial damage are important factors in the
pathophysiology and progression of diabetic nephropathy.
To examine whether markers of tubular damage are useful in
monitoring the progression of disease, we measured urinary
levels of neutrophil gelatinase-associated lipocalin (NGAL),
liver–fatty acid-binding protein (LFABP), and kidney injury
molecule-1 (KIM-1) in a 3-year intervention study of 63 type 1
diabetic patients with kidney disease. The baseline mean
glomerular filtration rate (GFR) was 87ml/min per 1.73m2
and urinary albumin excretion 1141mg/24h. Patients with
the highest compared with the lowest quartile of urinary
NGAL at baseline had higher urinary KIM-1 levels and a
significant decrease in their GFR each year. Using linear
regression analysis, we found that elevated urinary NGAL and
KIM-1 concentrations were associated with a faster decline
in GFR, but not after adjustment for known promoters of
progression. Urinary LFABP was not related to decline in GFR.
Losartan treatment (100mg/day) reduced urinary KIM-1
by 43% over a 12-month period. Thus, urine biomarker
measurements in patients with type 1 diabetic nephropathy
did not provide additional prognostic information to that of
known progression promoters.
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Diabetic nephropathy is a serious complication with high
morbidity and mortality. One-third of patients with diabetic
nephropathy develop end-stage renal disease (ESRD), and the
cumulative incidence of ESRD is 8% at 30 years after onset of
type 1 diabetes.1
As an attempt to prevent progression from diabetic
nephropathy to ESRD, numerous progression promoters have
been investigated and found to be essential targets for
intervention. This includes albuminuria, arterial blood pres-
sure, blood lipids, restriction of protein intake, and glycemic
control.2 Despite improved outcome due to aggressive multi-
factorial intervention, many patients still develop ESRD.3
Recently, studies have shown that not only glomerular but
also tubulointerstitial damage are important factors in the
pathophysiology and progression of diabetic nephropathy.4,5
Markers of tubular damage could, therefore, potentially be
useful in the evaluation of prognosis and for monitoring the
effect of intervention. Different markers of tubular damage
have been suggested in recent years: Some of the first and
most prominent were a1- and b2-microglobulin, and since
then many markers of tubular damage has been discovered.
Neutrophil gelatinase-associated lipocalin (NGAL) is a small
protein that belongs to the lipocalin protein family. NGAL is
produced in epithelia cells and neutrophils in most tissues
and is a marker of renal tubular damage.6 Mori and Nakao7
presented a review on the ‘forest fire theory’: They see the
ongoing nephron damage as buring trees, whereas trees/
nephrons which are already burned down/atrophic is not
producing NGAL, so NGAL is a result of the active damage:
the nephrons that can still be saved. They argue that NGAL is
representative of the functioning tubular mass and produced
as a response to tubular injury. Liver–fatty acid-binding
protein (LFABP) is an intracellular carrier protein also
produced in proximal tubular cells, as a response to
tubulointerstitial damage, and it reflects accurately the degree
of tubular injury.8 Another marker is kidney injury molecule-
1 (KIM1), which has been shown to be a marker of tubular
damage in various chronic kidney diseases.9
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Previously, we have shown that levels of the tubular
markers, urinary (u)-NGAL10 and u-LFABP,11,12 are in-
creased in type 1 diabetic patients, even before they develop
signs of glomerular damage, that is, micro- or macroalbu-
minuria. However, the role of u-NGAL and u-LFABP in the
further progression from diabetic nephropathy toward ESRD
in type 1 diabetes is unknown.
In the current work, we aimed to determine the role of
u-NGAL, u-KIM1, and u-LFABP as predictors of decline in
glomerular filtration rate (GFR) in patients with type 1
diabetes and diabetic nephropathy. This was carried out in a
3-year prospective intervention trial, initially designed to
investigate the long-term renoprotective effects of losartan
in 63 patients with type 1 diabetes and diabetic nephro-
pathy, with different angiotensin-converting enzyme ID
genotypes,13,14
In previous studies it has been shown that renin–angio-
tensin–aldosteron system blockade reduces apoptotic factors
in tubules and thereby preserves tubular function.15 On the
basis of this hypothesis we investigated the effect of the
angiotensin II receptor blocker losartan on the tubular
markers.
RESULTS
Sixty-three patients completed the study. Twenty-five patients
were women. Mean (s.d.) age was 44 (9) years and mean
duration of diabetes was 32 (9) years. At baseline, GFR was 87
(24) ml/min per 1.73m2 and the level of albuminuria
(geometric mean (95% confidence interval)): 1141
(930–1401) mg/24 h.
At baseline, after the wash out period (Figure 1), u-NGAL
was 1878 (1268–2781) (ng)/(g), u-LFABP was 1300 (743–2270)
(ng/g), and u-KIM1 was 59 (48–72) (ng/g). U-KIM1 and
u-NGAL at baseline were associated with u-albumin at
baseline (all log transformed; R¼ 0.44, P¼ 0.002 and
R¼ 0.31, P¼ 0.03), respectively: whereas u-LFABP was not
associated with u-albumin (R¼ 0.02).
Baseline levels of the three tubular markers were not
associated with baseline GFR (P40.4).
Decline in GFR
Decline in GFR during the 3-year study period was 4.1 (3.6)
ml/min per 1.73m2 per year. We found that patients with u-
NGAL in the highest versus the lowest quartile at baseline
had a decline in GFR of 6.8 versus 2.6ml/min per 1.73m2
(P¼ 0.01), and for u-KIM1 5.5 versus 2.6 (P¼ 0.04; see
Table 1). In a linear regression analyses, high levels of
u-NGAL (R¼ 0.32, P¼ 0.02) and u-KIM1 (R¼ 0.24, P¼ 0.1)
at baseline were associated with a faster decline in GFR, but
the association were not significant when adjusted for known
progression promoters as seen in Table 2 (sex, age, HbA1c,
systolic blood pressure, urinary albumin excretion rate). See
Figures 2 and 3 for scatter plots. U-LFABP did not predict
decline in GFR (R¼ 0.1, P¼ 0.5).
Effect of losartan
From baseline visit, without losartan treatment to full dose
100mg at 1 year, the effects of losartan were evaluated
(Figure 1 and Table 3). As previously reported, losartan
significantly reduced blood pressure and albuminuria. For
this study, we found that u-KIM1 was significantly reduced
by 43 (29–52)% and stayed at this level during 3-year follow-
up (see Figure 4a and b). The decline in u-KIM1 from 0 to 12
months was associated with change in u-albumin (R¼ 0.51,
Po0.001), but not with systolic blood pressure (R¼ 0.16,
P¼ 0.6), or decline in GFR during the study (R¼ 0.14,
P¼ 0.4). U-NGAL and u-LFABP were not significantly
affected by losartan treatment (increased 1% (39 to 29%)
and 34% (34 to 170%), respectively). The levels of u-LFABP
and u-NGAL did not change significantly during the 3-year
follow-up.
DISCUSSION
We found that in type 1 diabetic patients with diabetic
nephropathy high levels of the markers of tubular damage
U-KIM1, u-NGAL and u-LFABP, GFR, and 24 hr blood pressure
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Figure 1 |Design of the study.
Table 1 | Yearly decline in GFR according to baseline levels of markers of tubular damage
GFR decline (mean, s.d.)/year ml/min per 1.73m2
First quartile Second quartile Third quartile Fourth quartile P-value ANOVA/(lower vs upper quartile)
u-NGAL* 2.6 (1.9) 4.0 (3.7) 3.9 (3.3) 6.8 (4.4) 0.037/0.01
u-KIM1* 2.6 (2.8) 4.1 (2.9) 5.2 (4.7) 5.5 (3.7) 0.20/0.04
u-LFABP* 4.5 (3.4) 3.3 (3.9) 4.6 (4.7) 5.2 (3.1) 0.30/0.69
Abbreviations: ANOVA, analysis of variance; GFR, glomerular filtration rate; u-KIM1, urinary kidney injury molecule-1; u-LFABP, urinary liver–fatty acid-binding protein; u-NGAL,
urinary neutrophil gelatinase-associated lipocalin.
Analysis performed by ANOVA followed by comparison of the difference of decline in GFR between the upper and lower quartile.
*ng/g.
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u-NGAL and u-KIM1, but not u-LFABP, were predictive of
faster decline in GFR during 3-year of follow-up after onset
of antihypertensive treatment with the angiotensin II
receptor blocker losartan. However, the markers did not
provide additional prognostic information, as the association
between baseline levels of the markers and decline in GFR
was not independent of known progression promoters.
U-KIM1 was significantly reduced after onset of losartan
treatment, and this reduction was associated with the decline
in albuminuria.
In a study of 103 diabetic patients with varying degrees of
glomerulosclerosis, it was reported that estimated GFR was
not always related to glomerular damage. When there were
no tubulointerstitial damage, the patients had preserved
kidney function despite the glomerular damage, whereas a
reduced kidney function was observed in cases with
tubulointerstitial damage.16 This indicates that tubular
damage is not just a passive result of glomerular damage,
but has an independent role in the development of renal
impairment. However, this statement has been questioned
and another hypothesis suggested that the glomerular
damage and tubular damage are involved in early and late
damage in diabetic nephropathy, respectively.4
Mori and Nakao7 suggested that u-NGAL is a real time
indicator of renal damage: ‘the forest fire theory’ as described
in the introduction. They propose that u-NGAL do not, as
other markers of kidney damage, reflect the number of
remaining nephrons, but instead is a dynamic measure of
activity of disease. This conclusion was based on animal
studies. In 96 patients with chronic kidney disease, it has
been shown by Bolignano et al.17 that u-NGAL is predictive
of progression of chronic kidney disease (doubling of
s-creatinine/ESRD) even after adjustment for other progression
promoters (adjusted for serum NGAL, estimated GFR, and
age). However, in their study only 20% of the patients had
diabetic nephropathy, the other 80% had non-diabetic
nephropathy of various etiology. Our study extends their
findings as we also observed an association between u-NGAL
and decline in GFR; however, in our study this was not
independent of other progression promotors. Their follow-
Table 2 |Multiple regression analyses illustrating the influence of log-transformed u-NGAL, u-KIM1, and u-Alb and known
confounders on GFR decline per year
U-NGAL U-KIM1 U-Alb
Multiple R 0.33 0.33 0.54 0.24 0.25 0.54 0.43
b (s.e.) b (s.e.) b (s.e.) b (s.e.) b (s.e.) b (s.e.) b (s.e.)
Tubular marker 2.0* (0.87) 2.1* (0.9) 0.46 (1.2) 2.9 (1.7) 2.8 (1.8) 0.12 (2.3)
Sex 0.15 (0.2) 1.1 (1.4) 0.4 (1.2) 1.3 (1.3)
Age 0.01 (0.06) 0.01 (0.07) 0.01 (0.06) 0.01 (0.8)
Diabetes duration 0.05 (0.07) 0.1 (0.07)
HbA1c 0.35 (0.5) 0.34 (0.5)
Log u-albumin 4.0 (1.9) 4.1 (2.0) 4.4* (1.2)
Systolic blood pressure 0.05 (0.06) 0.05 (0.06)
Abbreviations: GFR, glomerular filtration rate; u-Alb, urinary albumin; u-KIM1, urinary kidney injury molecule-1; u-NGAL, urinary neutrophil gelatinase-associated lipocalin.
Reported values are b (-unstandardized) (s.e.), *Po0.05.
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Figure 2 | Scatter plot of baseline urinary neutrophil
gelatinase-associated lipocalin (u-NGAL) versus decline in
glomerular filtration rate (GFR) during the study period
(R¼ 0.32, P¼ 0.02).
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Figure 3 | Scatter plot of baseline urinary kidney injury
molecule-1 (u-KIM1) versus decline in glomerular filtration
rate (GFR) during the study period (R¼ 0.24, P¼ 0.1).
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up time was only 18 months compared with 3 years of
follow-up in this study. More important is that they reported
estimated GFR compared with our ‘true’ GFR measured with
plasma clearance of an external marker (51Cr-EDTA).
NGAL has mainly been investigated in late chronic kidney
disease, as recently reviewed by Bolignano et al.,18 and not
much in early nephropathy. In cross-sectional studies of
patients with earlier stages of diabetic nephropathy, we and
others have found that u-LFABP is associated with u-albumin
excretion levels (R¼ 0.73, Po0.001) and thereby reflects the
degree of kidney damage.12 In a prospective study of type 1
diabetic normoalbuminuric patients followed for a median of
18 years, we found that u-LFABP predicted development of
diabetic nephropathy.11 These patients were free of renal
complications at baseline. As u-LFABP levels were not
predictive of decline in GFR in the present study of patients
with overt diabetic nephropathy, this supports the idea that
the ‘tubular phase’ or damage reflected by u-LFABP is more
important in the early stages of diabetic nephropathy, and
thus the value of this tubular marker is greatest at that stage.
In this study we found, in a linear regression analysis, that
u-NGAL and u-KIM1 at baseline predicted the rate of decline
in GFR during 3 years of follow-up. This seems to be
mediated through the known progression promoters, as the
difference disappears after adjustment for these variables.
This suggests that the tubular damage reflected by increased
levels of these markers is important in the development and
further progression to ESRD. However, the fact that they are
not independently able to predict decline in GFR indicates
that there is no additional information obtained by
measuring them in this situation. The major change in the
model was seen when entering u-albumin excretion rate, as
the P-value for u-NGAL was changed to 0.7, indicating that
the effect of u-NGAL does not add to the effect of u-albumin
(see Table 3). This is in accordance with the correlation
between u-NGAL and urinary albumin excretion, although
the correlation was not strong. We have not been able to find
any studies, besides the present, in overt diabetic nephro-
pathy describing the relationship between u-NGAL/u-
LFABP/u-KIM1 and kidney function, as expressed by urinary
albumin excretion or GFR.
Urinary excretion of KIM1 is not only known to be closely
related to both the tubular production of KIM1 but is also
specific to tubular damage, as confirmed by biopsies in both
clinical and experimental studies.9,19 Another interesting
finding is that in studies of human biopsies with tubular
necrosis or atrophic and fibrotic damage, KIM1 is not
produced. The authors, therefore, conclude that KIM1 is a
good marker of active/ongoing tubular damage and not
tubular scarring.9 We found that the angiotensin II receptor
Table 3 | Effects of losartan on laboratory values measured at baseline and after 12 months treatment in 63 type 1 diabetic
patients with diabetic nephropathy
Losartan 0mg (baseline) Losartan 100mg (1 year) P-value
Systolic blood pressure (mmHg) 152 (17) 142 (16) o0.001
Diastolic blood pressure (mmHg) 80 (9) 73 (8) o0.001
GFR (ml/min per 1.73m2) 87 (24) 78 (23) o0.001
u-Albumin (mg/24h)a 1141 (930–1401) 469 (348–632) o0.001
u-KIM1a (ng/g) 59 (48–72) 38 (31–47) o0.001
u-LFABPa (ng/g) 1300 (743–2270) 1484 (884–249) 0.42
u-NGALa (ng/g) 1878 (1268–2781) 1794 (1305–2466) 0.95
Abbreviations: GFR, glomerular filtration rate; u-KIM1, urinary kidney injury molecule-1; u-LFABP, urinary liver–fatty acid-binding protein; u-NGAL, urinary neutrophil
gelatinase-associated lipocalin.
aGeometric mean (95% confidence interval).
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Figure 4 | Effect of losartan on tubular markers. (a) Reductions
in log-transformed urinary kidney injury molecule-1 (u-KIM1)
during losartan treatment. KIM1 is significantly decreased from
baseline (no difference from 1 to 3 years). Error bars indicate 95%
confidence interval. (b) Reductions in log-transformed u-KIM1
during losartan treatment, expressed in percentages.
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blocker losartan reduces u-KIM1 significantly with 43%.
Experimental studies in diabetic rats have shown that
renin–angiotensin–aldosteron system blockade reduces apop-
totic factors and thereby preserves tubular function.15 It has
been hypothesized that the reduced tubular damage seen
when blocking the renin–angiotensin system is due to
reduced oxidative stress and correction of chronic hypoxia,
independently of the blood pressure-lowering effect.15 This is
in accordance with findings in non-diabetic nephropathy. In
a study of 34 non-diabetic patients with proteinuria, losartan
was found to reduce u-KIM1 excretion with B30%,20 this
was highly associated with the decrease in proteinuria. The
authors speculated that the treatment induced reduction in
albuminuria, which led to reduced albumin toxicity on the
tubules. However in this study, only part of the reduction in
u-KIM1 can be explained by reduced tubular albumin
toxicity (R¼ 0.53, Po0.001), and furthermore the reduction
was not related to decline in GFR.
In our study, we hypothesized that patients with the
largest decrease in tubular markers would benefit most
(smallest decline in GFR) during follow-up time. However,
this was not the case (change in u-KIM1 versus GFR decline
during the study: R¼ 0.14, P¼ 0.4). Baseline u-KIM1 (that
is, tubular damage) itself was a better marker than change,
which could not only reflect tubular repair (and our study
could lack the power to show such an effect), but also
changes induced by losartan, which were not related to effect
on decline in GFR, in which case an association between
change and decline could not be expected. Finally, it is not
possible to exclude that the association with baseline KIM1
could be due to confounding.
U-LFABP and u-NGAL were not reduced during long-
term losartan treatment in this study. We have previously
found that in type 1 diabetic patients with nephropathy,
treatment with the angiotensin-converting enzyme inhibitor
lisinopril for 8 weeks reduced u-LFABP by 40% (Po0.05),12
independently of the reduction in urine albumin excretion,
and u-NGAL with 17% (not significant).10 Whether the
difference between the studies could be explained by the use
of angiotensin-converting enzyme inhibitor versus angioten-
sin II receptor blocker, or rather if there is a short-term effect
of renin–angiotensin–aldosteron system blockade on the
markers, which disappears with time, will need to be
investigated further in future studies.
To our knowledge this is the first prospective study in
diabetic nephropathy comparing u-NGAL, u-KIM1, and
u-LFABP with ‘true’ GFR measurements based on plasma
clearance of 51Cr EDTA and a long follow-up period. Other
studies in chronic kidney disease have primarily been cross-
sectional, and prospective studies have mainly been per-
formed in non-diabetic patients with chronic kidney disease
with change in estimated GFR as the end point.
It is a limitation that we did not have access to renal
biopsies in the subjects, as the diagnosis was made clinically
according to established criteria. If biopsies had been
available, they could have potentially confirmed our hypoth-
esis that the renal production of the tubular markers are
closely related to the urinary excretion and that the tubular
markers reflect the tubular damage and tubular functioning
mass accurately. Moreover, this could have resulted in
evaluation of the functioning glomerular mass. This would
be interesting and relevant to look into in future studies.
However, as mentioned previously, this has been demon-
strated in several previous studies.8,9,18
A potential limitation of this study is the storage of the
samples at 20 1C for 10 years before analysis; however, all
samples were stored in similar conditions. It has previously
been shown that u-NGAL is stable after long-term storage at
20 1C.21 Regarding u-LFABP, it has been shown to be stable
after freezing (personal communication T Sugaya, unpub-
lished data). Another limitation is that we only had one urine
per visit available for tubulus marker measurement.
In conclusion, we found that type 1 diabetic patients with
high levels of u-NGAL and u-KIM1 are associated with a
faster decline in GFR, suggesting that tubular damage is
important for progression, even though the markers did not
add information about progression or treatment effect
beyond known progression promoters. Furthermore, patients
treated with the angiotensin II receptor blocker, losartan, had
a significant reduction in u-KIM1. More studies are needed
to determine the role of tubular damage, expressed by
excretion of u-NGAL, u-KIM1, and u-LFABP, in diabetic
nephropathy.
MATERIALS AND METHODS
The study was a 3-year prospective intervention trial initially
designed to investigate the long-term renoprotective effects of
losartan in 63 patients with type 1 diabetes and diabetic
nephropathy, with different angiotensin-converting enzyme ID
genotypes.13 For this study, we determined u-LFABP, u-NGAL,
and u-KIM1 at baseline and yearly during follow-up (for design, see
Figure 1).
Diabetic nephropathy was diagnosed clinically in patients with
persistent albuminuria (4300mg/24 h), diabetic retinopathy, and
absence of other evidence of kidney or renal tract disease. Before
enrollment, all antihypertensive medication was withdrawn for at
least 4 weeks. All patients fulfilled the following inclusion criteria:
diabetic nephropathy, GFR 460ml/min per 1.73m2, office blood
pressure4135/85mmHg, and age between 18 and 70 years. Dietary
intake of protein or salt was not restricted.
All antihypertensive medication was withdrawn for at least 4
weeks before enrolment. Thereafter, at baseline, patients were treated
with losartan at a dose of 50mg once daily for the first 2 months and
100mg once daily for the remainder of the study. Additional
antihypertensive treatments, that is, diuretics, calcium channel
blockers, and a-blockers, were given in an attempt to achieve a
target blood pressure of below 135/85mmHg. Blood pressure
measurements and adjustments of antihypertensive treatment were
determined every 3 months.
Glomerular filtration rate, u-albumin excretion rate, and 24 h
blood pressure were determined at baseline and every 6 months
thereafter, as described previously.13 Laboratory variables were
determined at baseline as well as at the first (after 2 months) and last
visit during losartan treatment.
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Glomerular filtration rate was measured as plasma clearance of
an intravenous injection of 51Cr-EDTA.22 The results were
standardized for 1.73m2 body surface area, using the same surface
for each patient during the study. The mean coefficient of variation
in GFR of each patient from day to day was 4%.
Albumin excretion rate was determined as the geometric mean of
at least two consecutive 24-h urine collections, completed at baseline
and immediately before each visit.
The tubular markers, u-NGAL, u-LFABP, and u-KIM1 (ELISA,
Roche, Penzberg, Germany), were measured in one 24 h urine
sample at baseline, after wash out and yearly thereafter and
expressed relative to u-creatinine.
From venous blood samples, HbA1c, serum potassium, sodium,
creatinine, and cholesterol concentrations were determined, and
blood pressure values were determined based on 24-h ambulatory
blood pressure measurements performed using the Takeda TM2420
device (version 7; A&D, Tokyo, Japan; for details see ref. 13).
This study was performed according to the principles of the
Declaration of Helsinki and approved by the ethical committee of
Copenhagen County. All patients gave their informed consent.
Statistic analysis
Data are expressed as means (s.d.), except for u-albumin, u-LFABP,
u-NGAL, and u-KIM1, which were logarithmically transformed
owing to their skewed distribution, and given as the geometric
means (95% confidence interval). The rate of decline in kidney
function was analyzed with regression lines for GFR over the follow-
up period using all measurements of GFR during the study period.
Comparisons of normally or log-normally distributed variables were
performed using Student’s t-test. When quartiles were compared,
analysis of variance with subsequent comparison of bottom versus
top quartile was performed. Univariate and multivariate linear
regression analysis were used to determine the association between
tubular markers and decline in GFR. Association between changes in
tubular markers and changes in urinary albumin excretion and GFR
were evaluated with linear regression. We adjusted for the following
known progression promotors in our analysis: sex, age, diabetes
duration, HbA1c, systolic blood pressure, and urinary albumin
excretion rate.
A P-value o0.05 was considered significant (two tailed). Data
were analyzed using the commercially available statistical program
SPSS 14.0 software program (SPSS, Chicago, IL).
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